Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine.

Kelly-Quintos C, Kropec A, Briggs S, Ordonez CL, Goldmann DA, Pier GB.

J Infect Dis. 2005 Dec 1;192(11):2012-9. Epub 2005 Nov 1.

PMID:
16267775
2.

Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.

Pier G.

Expert Rev Vaccines. 2005 Oct;4(5):645-56. Review.

PMID:
16221066
3.

Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine.

Maira-Litrán T, Kropec A, Goldmann DA, Pier GB.

Infect Immun. 2005 Oct;73(10):6752-62. Erratum in: Infect Immun. 2005 Nov;73(11):7789.

4.

Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children.

Adem PV, Montgomery CP, Husain AN, Koogler TK, Arangelovich V, Humilier M, Boyle-Vavra S, Daum RS.

N Engl J Med. 2005 Sep 22;353(12):1245-51.

5.

Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.

Domanski PJ, Patel PR, Bayer AS, Zhang L, Hall AE, Syribeys PJ, Gorovits EL, Bryant D, Vernachio JH, Hutchins JT, Patti JM.

Infect Immun. 2005 Aug;73(8):5229-32.

6.

Protective antibodies and endemic dimorphic fungi.

Nosanchuk JD.

Curr Mol Med. 2005 Jun;5(4):435-42. Review.

PMID:
15977999
7.

Antibodies: can they protect against HIV infection?

Mc Cann CM, Song RJ, Ruprecht RM.

Curr Drug Targets Infect Disord. 2005 Jun;5(2):95-111. Review.

PMID:
15975016
8.

Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers.

Reilley S, Wenzel E, Reynolds L, Bennett B, Patti JM, Hetherington S.

Antimicrob Agents Chemother. 2005 Mar;49(3):959-62.

9.

A crucial role for exopolysaccharide modification in bacterial biofilm formation, immune evasion, and virulence.

Vuong C, Kocianova S, Voyich JM, Yao Y, Fischer ER, DeLeo FR, Otto M.

J Biol Chem. 2004 Dec 24;279(52):54881-6. Epub 2004 Oct 22. Erratum in: J Biol Chem. 2005 Mar 25;280(12):12064.

10.

Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains.

Pier GB, Boyer D, Preston M, Coleman FT, Llosa N, Mueschenborn-Koglin S, Theilacker C, Goldenberg H, Uchin J, Priebe GP, Grout M, Posner M, Cavacini L.

J Immunol. 2004 Nov 1;173(9):5671-8. Erratum in: J Immunol. 2007 Jun 1;178(11):7485.

11.

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB.

Clin Infect Dis. 2004 Aug 1;39(3):309-17. Epub 2004 Jul 15. Erratum in: Clin Infect Dis. 2005 Apr 1;40(7):1077. Clin Infect Dis. 2004 Oct 1;39(7):1093.

PMID:
15306996
12.

Therapeutic antibodies.

Groner B, Hartmann C, Wels W.

Curr Mol Med. 2004 Aug;4(5):539-47. Review.

PMID:
15267225
13.

Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.

Fenton C, Scott LJ, Plosker GL.

Paediatr Drugs. 2004;6(3):177-97.

PMID:
15170364
14.

Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials.

Fattom AI, Horwith G, Fuller S, Propst M, Naso R.

Vaccine. 2004 Feb 17;22(7):880-7. Review.

PMID:
15040941
15.

Identifying epitopes of HIV-1 that induce protective antibodies.

Zolla-Pazner S.

Nat Rev Immunol. 2004 Mar;4(3):199-210. Review. No abstract available.

PMID:
15039757
16.

Long-term outcome and quality of care of patients with Staphylococcus aureus bacteremia.

Fätkenheuer G, Preuss M, Salzberger B, Schmeisser N, Cornely OA, Wisplinghoff H, Seifert H.

Eur J Clin Microbiol Infect Dis. 2004 Mar;23(3):157-62. Epub 2004 Feb 25.

PMID:
14986158
17.

Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen.

Pier GB.

Carbohydr Res. 2003 Nov 14;338(23):2549-56. Review.

PMID:
14670716
18.

Infliximab treatment of rheumatoid arthritis and Crohn's disease.

Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH.

Ann Pharmacother. 2003 Sep;37(9):1256-65. Review.

PMID:
12921510
19.
20.

Antimicrobial resistance: the example of Staphylococcus aureus.

Lowy FD.

J Clin Invest. 2003 May;111(9):1265-73. Review. No abstract available.

Supplemental Content

Support Center